Spectrum Of Activity
Usual dose20-30 mg/kg PO q24h (max 2 g)
BW <50 kg: 1 g PO q24h
BW 50-70 kg: 1.5 g PO q24h
BW >70 kg: 2 g PO q24h
30 mg/kg PO div q12-24h
Severe hepatic impairmentAvoid
CrCl ≥10CrCl <10HD20-30 mg/kg PO q24h12-20 mg/kg PO q24h25 mg/kg q48h (give after hemodialysis on dialysis days)
A first-line anti-tuberculosis drug.
Obtain acid-fast bacilli smear and culture from sputum until 2 consecutive culture specimens are negative.
Perform chest x-rays after 2-3 months of treatment and at end of treatment.
Perform liver function tests at baseline, periodically during therapy, and if any clinical signs or symptoms occur, especially in patients with preexisting liver disease or those at increased risk for drug-related hepatitis (e.g. alcohol users).
Obtain uric acid levels at baseline, periodically during therapy, and if any clinical signs or symptoms occur.
Elevated liver enzymes level
Zidovudine - decreased efficacy
Ethionamide - may result in hepatotoxicity
Rifampin - may result in severe hepatic injury
Cyclosporine - reduced serum concentrations
Antimicrobial agent: Antimycobacterial agent
Pregnancy category: C
Average serum half life: 9-10 hours
CSF penetration: Therapeutic
Discontinue use and do not resume if hyperuricemia with acute gouty arthritis occurs.
Patients with preexisting liver disease or increased risk of drug-related hepatitis; close monitoring recommended.
Discontinue use and do not resume if signs of hepatocellular damage occur.
Susceptibility tests recommended.